Skip to main content

Table 1 Studies on asthma

From: Health-related quality of life measurement in asthma and chronic obstructive pulmonary disease: review of the 2009-2014 literature

Drugs

Baseline

Final score

Statistical significancea

Clinical significance

Reference

flut/form 500/20 μg

4.42 ± 0.89

5.34 ± 1.07

P = 0.036

 

Bodzenta-Lukaszyk et al. Resp Med 105 674-682 2011 [13]

flut + form 500 + 24 μg

4.57 ± 0.99

5.30 ± 1.00

flut/form250/10 μg

Not reported

Mean improvement of 0.8 in both treatment groups

ns

55 %

Bodzenta-Lukaszyk et a.l Journal of Asthma 49(10), 1060-1070, 2012 [14]

bud/form400/12 μg

57.6 % ns

flut/form combo

4.8 ± 1.1

5.5 ± 1.1

ns

Not available

Bodzenta-Lukaszyk et al. Current Medical Research and Opinion 29, 5 579-588, 2013 [15]

flut + form

4.9 ± 1.2

5.6 ± 1.0

Tio 5 μg add on

4.8 in all groups

Change of 0.1 points for both active treatments compared with placebo

ns

Not available

Kerstjens et al. Journal of Allergy Clin Immunol 128, 2 308-314, 2011 [16]

Tio 10 μg add on

Plac add on

Trial 1

   

Not achieved

Kerstjens et al. New England Journal of Medicine 367:1198-1207, 2012 [17]

Tio 5 μg/die add on

4.6 ± 1.1

5.15

Ns

plac add on

4.6 ± 1.1

5.1

Ns (p < 0.05 al week 24

Trial 2

  

Tio 5 μg/die add on

4.6 ± 1.0

5.1

plac add on

4.7 ± 1.1

4.93

Bud/formSMART

4.78

4.81

ns

Not available – measurement of Satisfaction with Asthma Treatment Questionnaire

Louis R et al. The International Journal of Clinical Practice 63, 10 1479-1488, 2009 [18]

Conventional best practice

4.78

4.82

Tio

 

5.58

P = 0.01

Not available

Peters et al. New England Journal of Medicine 363 18 1715-1726, 2010 [19]

Double glucocorticoid

5.43 ± 1.05

5.48

P = 0.38

salm

 

5.71

P < 0.001

Flut fur/vil 200/25 μg

Not available

Baseline + 0.93 ± 0.065

ns

Not available

O’Byrne et al. Eur. Resp. Journal 43 773-782, 2014 [20]

Flut fur.200 μg

 

Baseline + 0.88 ± 0.071

Flut prop.500 μg

 

Baseline + 0.90 ± 0.068

Flut. fur/vil 100/25 μg

5.35

5.85

ns

46 %

Woodcock et al. Chest 144(4), 1222-1229, 2013 [21]

flut. pro/salm 250/50 μg

5.37

5.79

 

38 %

salm 50 μg

5.175

Baseline + 0.280

ns

Not available

Bateman et al. J. Allergy Clin Immunol128, 315-322, 2011 [22]

tio 5 μg

 

Baseline + 0.131

plac

 

Baseline + 0.039

 

Not available

Adjustable bud/form

AQLQ

AQLQ

AQLQ

AQLQ

O’Connor et al. Journal of Asthma 47 217-223, 2010 [10]

Fixed bud/form

Not available

Not available

P < 0.04*

66.7 %

Adjustable bud/form

  

Nsb

63.0 %

    

61.9 %

    

No clinical difference between groups

  1. aBetween groups
  2. bFixed-dose regimen baseline vs end of treatment
  3. *Adjustable dosing vs fixed dose regimen
  4. p ≤ 0.002 vs fluticasone propionate/salmeterol